Skip to main content

Zentalis Pharmaceuticals, Inc. (ZNTL)

NASDAQ: ZNTL · IEX Real-Time Price · USD
78.58 1.35 (1.75%)
Oct 21, 2021 2:20 PM EDT - Market open
Market Cap3.59B
Revenue (ttm)n/a
Net Income (ttm)-179.33M
Shares Out40.74M
EPS (ttm)-4.50
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume69,215
Open77.13
Previous Close77.23
Day's Range76.05 - 78.93
52-Week Range34.48 - 81.40
Betan/a
AnalystsStrong Buy
Price Target85.11 (+8.3%)
Est. Earnings DateNov 8, 2021

About ZNTL

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidates are the ZN-c5, an oral selective estrogen receptor degrader that is in a Phase 1/2 clinical trial for the treatment of advanced estrogen receptor-positive, human epidermal growth factor receptor 2-negative, or advanced or metastatic breast cancer; and ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 1/2 clinical tri...

IndustryBiotechnology
IPO DateApr 3, 2020
Employees124
Stock ExchangeNASDAQ
Ticker SymbolZNTL
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 5 analysts, the average rating for ZNTL stock is "Strong Buy." The 12-month stock price forecast is 85.11, which is an increase of 8.31% from the latest price.

Price Target
$85.11
(8.31% upside)
Analyst Consensus: Strong Buy

News

Zentalis Pharmaceuticals Announces First Patient Dosed in the Phase 1/2 Study of ZN-c3 in Combination with Gemcitabin...

Initial results are expected in 2H 2022 Initial results are expected in 2H 2022

1 month ago - GlobeNewsWire

Zentalis Pharmaceuticals Announces Publication in the Journal of Medicinal Chemistry Highlighting the Discovery of it...

NEW YORK and SAN DIEGO, Sept. 01, 2021 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small molecule ...

1 month ago - GlobeNewsWire

Zentalis Pharmaceuticals Reports Second Quarter 2021 Financial Results and Operational Update

Reported promising new interim data on both ZN-c3 and ZN-c5, highlighting their potentially best-in-class profiles

2 months ago - GlobeNewsWire

Zentalis Pharmaceuticals Announces First Patient Dosed in Potentially Registrational Phase 2 Study of ZN-c3 in Patien...

NEW YORK and SAN DIEGO, Aug. 02, 2021 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small molecule t...

2 months ago - GlobeNewsWire

Zentera Therapeutics Announces Closing of $75 Million Series B Financing

Proceeds will be used to advance the development of three Zentalis-discovered oncology clinical candidates as well as business development for future pipeline additions in China Proceeds will be used to...

2 months ago - GlobeNewsWire

Zentalis Pharmaceuticals Announces Closing of Offering of Common Stock and Full Exercise of Underwriters' Option to P...

NEW YORK and SAN DIEGO, July 01, 2021 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small molecule t...

3 months ago - GlobeNewsWire

Zentalis Secures $150M In Equity Funding

Zentalis Pharmaceuticals Inc (NASDAQ: ZNTL) priced an underwritten public offering of 3.1 million shares at $48.50 per share, for gross proceeds of approximately $150.4 million. The stock's last close p...

3 months ago - Benzinga

Zentalis Pharmaceuticals Announces Pricing of Offering of Common Stock

NEW YORK and SAN DIEGO, June 28, 2021 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small molecule t...

3 months ago - GlobeNewsWire

Zentalis Pharmaceuticals Announces Proposed Public Offering of Common Stock

NEW YORK and SAN DIEGO, June 28, 2021 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small molecule t...

3 months ago - GlobeNewsWire

Lengo Therapeutics Appoints Enoch K. Kariuki as Chief Executive Officer

SAN DIEGO--(BUSINESS WIRE)-- #LengoTx--Lengo Therapeutics, a biopharmaceutical company developing novel precision medicines targeting driver mutations in oncology, today announced the appointment of Eno...

3 months ago - Business Wire

Zentalis Pharmaceuticals to Participate in the Jefferies Virtual Healthcare Conference

NEW YORK and SAN DIEGO, May 28, 2021 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small molecule th...

4 months ago - GlobeNewsWire

Zentalis Pharmaceuticals Reports First Quarter 2021 Financial Results and Operational Update

Reported robust initial results from the Phase 1 monotherapy dose escalation trial of its WEE1 inhibitor, ZN-c3, demonstrating single-agent activity and Exceptional Responses in heavily pre-treated pati...

5 months ago - GlobeNewsWire

Zentalis's Early WEE1 Inhibitor Data Shows 'Exceptional' Response In Solid Tumor Study, Plans Combination Trials

Zentalis Pharmaceuticals Inc (NASDAQ: ZNTL) has announced initial efficacy and safety data from the Phase 1 dose-escalation portion of its ongoing Phase 1/2 trial evaluating ZN-c3 in patients with advan...

6 months ago - Benzinga

Zentalis Pharmaceuticals Enters into Clinical Collaboration and Supply Agreement with GlaxoSmithKline to Evaluate its...

ZN-c3 is currently being evaluated in patients with advanced solid tumors and ovarian cancer ZN-c3 is currently being evaluated in patients with advanced solid tumors and ovarian cancer

6 months ago - GlobeNewsWire

Zentalis Pharmaceuticals Announces Promising Initial Data Presented in a Late-Breaking Session at AACR on ZN-c3, its ...

ZN-c3 demonstrated single agent activity, generating Exceptional Responses in a range of heavily pre-treated solid tumors

6 months ago - GlobeNewsWire

Zentalis Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Operational Update

Initiated multiple early-stage clinical trials evaluating its oral SERD, ZN-c5, WEE1 inhibitor, ZN-c3 and BCL-2 inhibitor, ZN-d5

6 months ago - GlobeNewsWire

Zentalis Pharmaceuticals Announces Late-Breaker Oral Presentation on WEE1 Inhibitor, ZN-c3, at the AACR Annual Meetin...

Additional preclinical data on ZN-c3 and the Company's EGFR inhibitor, ZN-e4, will be presented as poster presentations Additional preclinical data on ZN-c3 and the Company's EGFR inhibitor, ZN-e4, will...

7 months ago - GlobeNewsWire

Zentalis Pharmaceuticals to Present Initial Clinical Data on ZN-c3 at the AACR Annual Meeting 2021

NEW YORK and SAN DIEGO, Feb. 24, 2021 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small molecule t...

7 months ago - GlobeNewsWire

Zentalis Pharmaceuticals Announces the Appointment of Dr. Enoch Kariuki to its Board of Directors

NEW YORK & SAN DIEGO, Feb. 10, 2021 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small molecule the...

8 months ago - GlobeNewsWire

Zentalis Pharmaceuticals to Participate in Two Upcoming Investor Conferences

NEW YORK and SAN DIEGO, Feb. 05, 2021 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small molecule t...

8 months ago - GlobeNewsWire

Why Earnings Season Could Be Great for Zentalis (ZNTL)

Zentalis (ZNTL) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

8 months ago - Zacks Investment Research

Andreas Halvorsen Pulls Back Zentalis Pharmaceuticals Holding

Andreas Halvorsen (Trades, Portfolio) has revealed a reduction in his holding of Zentalis Pharmaceuticals Inc. (NASDAQ:ZNTL), according to GuruFocus' Real-Time Picks, a Premium feature.

10 months ago - GuruFocus

Zentalis Pharmaceuticals to Participate In Two Upcoming Investor Conferences

NEW YORK and SAN DIEGO, Nov. 12, 2020 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small molecule t...

11 months ago - GlobeNewsWire

Zentalis Pharmaceuticals to Host a Key Opinion Leader Virtual Meeting to Discuss its Investigational WEE1 Inhibitor Z...

Live webcast to be held on September 24th at 12:00 p.m. EDT Live webcast to be held on September 24th at 12:00 p.m. EDT

1 year ago - GlobeNewsWire

Zentalis Pharmaceuticals Appoints Alexis Pinto as Chief Legal Officer

NEW YORK and SAN DIEGO, Sept. 01, 2020 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small molecul...

1 year ago - GlobeNewsWire